News
Dopavision Provides Clinical Trial Update and Announces All MyopiaX-1 Trial Sites Are Active
– First-in-human clinical trial of MyopiaX®, the first therapeutic approach in juvenile myopia to target the dopamine pathway digitally
– Enrollment ongoing in Germany, Spain, the Netherlands, and the United Kingdom
Dopavision, a clinical-stage company developing innovative solutions for the management of myopia, today announced an update on its MyopiaX-1 trial (NCT04967287). All clinical trial centers are now open and are actively screening and enrolling study participants, providing trial access to eligible children with myopia across Germany, Spain, the Netherlands, and the United Kingdom.
Thermosome Announces Participation in IMAGIO Consortium to Improve Cancer Treatment
– IMAGIO consortium of clinical partners coordinated by Philips receives EUR 24 million grant from the Innovative Health Initiative (IHI) and additional funding from industry partners to support the research tracks
– Consortium aims to improve clinical outcomes through less invasive treatments for lung cancer, liver cancer and soft tissue sarcomas
Thermosome, a drug development company specializing in targeted tumor therapies, today announced its participation in the IMAGIO consortium set out to develop innovations in interventional oncology focused on lung cancer, liver cancer and soft tissue sarcomas (STS). The IMAGIO consortium, consisting of approximately 30 clinics, academic institutes, healthcare companies, and patient organizations, has been awarded a EUR 24 million grant from the Innovative Health Initiative, complemented by additional funding from industry partners to conduct research on less invasive cancer treatments.
BellaSeno Demonstrates Superior Biomechanical Properties of its 3-D Printed, Resorbable Scaffolds for Bone Reconstruction
— Data presented at the 24th EFFORT Congress in Vienna (Austria)
BellaSeno GmbH, an ISO 13485-certified medtech company developing resorbable scaffolds using additive manufacturing technologies, today announced comparative data on the biomechanical properties of different polycaprolactone/hydroxylapatite bone reconstruction scaffolds. The results, presented at the 24th EFORT Congress in Vienna, Austria, demonstrate that BellaSeno’s established manufacturing process results in bone scaffolds that can withstand higher loads and longer stress cycles than those produced by competing technologies.
MetrioPharm Receives Orphan Drug Designation for the Treatment of Duchenne Muscular Dystrophy
— FDA grants orphan drug designation for MetrioPharm’s lead compound MP1032 for the treatment of Duchenne muscular dystrophy (DMD)
— DMD is a designated orphan disease in both Europe and the U.S.
— MetrioPharm’s development objectives: better tolerability of existing therapies and improved efficacy in long-term treatment of DMD patients
MetrioPharm AG, a pharmaceutical company developing drugs for inflammatory and infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for MP1032 for the treatment of Duchenne muscular dystrophy.